A lthough there are different mechanistic theories for aging, 1 endothelial dysfunction (ED) is a rather neglected player in the aging process. A maladaptive insulin/IGF-1-like signaling (IIS) has a remarkable importance in proaging mechanisms, and insulin has direct effects on ED.
Endothelial Dysfunction: Consequence and Predictor of Insulin Resistance and Metabolic Diseases
ED is considered a common ground of type 2 diabetes (T2DM) and cardiovascular disease (CVD). 3 The ability of insulin to recruit nutritive capillaries that receive little or no blood flow in fasting conditions is a component of insulin-mediated glucose uptake. Therefore, in the capillary and arteriolar beds, which are in intimate contact with metabolically active insulin-sensitive tissues, ED leads to insulin resistance and T2DM. 4 The relationship between ED and glucose tolerance is experimentally and clinically solid. Insulin-mediated glucose uptake is lower in eNOS À/À mice than in wild-type C57Bl/6 mice, 5 as insulin induces vasodilatation in the skeletal muscle via increasing NO. 6 In addition, genetic manipulation of the insulin signaling pathway leads to ED and insulin resistance. [7] [8] [9] Stehouwer and colleagues proposed that insulin resistance syndrome (or metabolic syndrome) components can be viewed as diverse consequences of ED. 10 More specifically, these authors hypothesized that approximately 40% of insulin-mediated glucose uptake by skeletal muscle can be attributed to capillary recruitment; according to this hypothesis, microvascular dysfunction not only precedes and predicts the development of T2DM but also constitutes one of the links between insulin resistance and hypertension in metabolic syndrome.
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Consistent with this view, elevated levels of endothelial activation biomarkers such as ICAM-1 and other adhesion molecules predict incident diabetes. 12, 13 Based on these data, it is reasonable that ED predicts insulin resistance and diabetes that, in turn, anticipate and accelerate the aging process. Aging is also typically associated with impaired glucose tolerance, mainly because of a decline in insulin action. 14, 15 In contrast, high insulin sensitivity is linked to longevity, and parental longevity is inversely correlated with the risk of diabetes. 16, 17 A remarkable body of data in support of this mutual relationship is also available and detailed in other reviews. 18 From these works, it emerges that (1) insulin resistance can lead to ED, (2) ED can contribute to insulin resistance, and (3) both insulin resistance and ED accelerate aging.
Aging in the Vascular System
The life expectancy of diabetic individuals is estimated to be lower than that of the general population by 9.1 years among males and 6.7 years among females. 19 The identification of longevity-associated genes in the vascular endothelium, along with evidence of their abnormal expression in the context of ED and insulin resistance, suggests that in the aging process, endothelial dysfunction and insulin resistance are intimately linked.
The Sirtuin System in Metabolism and Endothelial Function
Caloric restriction (CR) is the most consistent experimental model of increased life span and protection from aging-associated diseases. Evidences indicate that the positive effects that CR exerts on diabetes and CVD are mediated by sirtuins. A decade ago, the silent information regulator 2 (SIR2) gene was shown to extend the life span of budding yeast. Since then, much has been understood about sirtuin biology, 20 and although their effect on life span has been disputed, new data confirmed that sirtuin action is relevant for the improvement of metabolic disorders. 21, 22 Importantly, animal and human studies have shown that CR prevents diabetes and protects from CVD. The mammalian sirtuin (Sirt)-1 is highly expressed in endothelial cells and controls functions that are critical to suppressing the development of atherosclerosis. 23 A series of experimental studies have shown that Sirt1 plays a role in improving the function of endothelial cells (Table) . Endothelial senescence is associated with a progressive decline of eNOS function and Sirt1 expression, having Sirt1 itself a role on eNOS through deacetylation at lysines 496 and 506 in the calmodulin-binding domain. 23 The reduction of Sirt1 is associated with upregulation of specific microRNAs such as mir-217 and mir-34. 41 Specific antagonism of mir-217 was shown to counteract endothelial senescence in different endothelial cell lineages. Furthermore, expression of mir-217 and Sirt1 was negatively correlated in atherosclerotic tissues, suggesting that factors increasing MiR-217 can promote endothelial senescence. Interestingly, hyperglycemia was shown to increase MiR-217, promoting diabetes complications. 46 In addition, overexpression of Sirt appears to postpone the senescent phenotype of endothelial cells through Sirt-induced epigenetic modifications of protein or through mir-34a. 38 Collectively, these results are consistent with the concept that Sirt1 activity plays a major role in the prevention of CVD. We showed that insulin resistance and subclinical atherosclerosis are associated with Sirt1 downregulation in monocytes and atherosclerotic plaques 47 ; in addition, glucotoxicity and lypotoxicity appear to quench Sirt1 expression in monocytic cells. The pathophysiological meaning of depressed Sirt1 expression in monocytes has been demonstrated in C57Bl/6 mice with a targeted deletion of Sirt1 in macrophages (Lys-Cre), which showed a metabolic syndrome-like phenotype. 48 In subjects at risk for diabetes, downregulation of Sirt1 resulting from metabolic toxicity reduced the expression of tissue inhibitor of metalloproteinase 3 (TIMP3), a protease inhibitor with antidiabetic and antiatherosclerotic functions. [49] [50] [51] [52] TIMP3 exerts its functions mainly through the inhibition of ADAM-17, also known as TNF-alpha converting enzyme. Specifically, hyperglycemia and hyperlipidemia reduced Sirt1 activation of the TIMP3 promoter, which caused increased endothelial activation and inflammation within atherosclerotic plaques in diabetic subjects. 51 Because soluble adhesion molecules such as VCAM-1 
p66Shc, Endothelial Biology, and Metabolism
Another important mediator that is activated by altered glucose metabolism and is involved in vascular senescence is p66Shc, which operates as a redox enzyme and is linked to apoptotic cell death. 57 Protein kinase C (PKC), which is induced by hyperglycemia, activates the mitochondrial localization of p66Shc, which in turn induces oxidative stress. 58 In agreement with its pro-oxidant feature, p66Shc's genetic deletion increases life span in SV/129 mice by about 30%. 59 We found that p66Shc expression is increased in peripheral blood mononuclear cells of T2DM patients compared with controls and is correlated with the degree of systemic oxidative stress. 60 In addition, the expression of p66Shc is increased in the setting of experimental ED. 61 SV/129 p66Shc À/À mice are protected against experimental diabetic p66Shc À/À SV/129 mice are also protected against hyperglycemia-induced ED through reduced peroxynitrite generation and lipid peroxidation and enhanced antioxidant defenses. 66 The mechanism is probably mediated by the ability of p66Shc to inhibit Akt signaling and eNOS phosphorylation. 67 p66Shc appears to also exert a relevant role in terms of vascular "metabolic memory." Paneni et al 68 showed that in human aortic endothelial cells exposed to high glucose and aortas of diabetic SV/129 mice, activation of p66Shc by protein kinase C bII persisted after returning to normoglycemia. Deletion of p66Shc also protects from ischemia/reperfusion brain injury through blunted production of free radicals in C57Bl/6 mice. 69 The relationship between aging, ED, and p66Shc was further explored by Francia et al, 70 who found that p66Shc À/À SV/129 mice showed an endothelial phenotype consistent with delayed aging. The link between p66Shc and ED is substantiated by the finding that p53 induces the expression of p66Shc, especially in response to angiotensin II, which in turn impairs endothelium-dependent vasomotor function. 71 In the macrovasculature, deletion of p66Shc prevents the development of early atherosclerotic lesions in SV/129 mice fed a high-fat diet 72 and reduces the development of advanced atherosclerosis in the ApoE À/À mouse model on a mixed SV/129-C57Bl/6 background.
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p66Shc also emerges as an important link between vascular disease and metabolism. p66Shc-generated oxidative stress is crucial for the development of visceral fat through modulation of the insulin signal and thermoinsulation. Indeed, p66Shc À/À mice are resistant to obesity induced by diet and leptin deficiency. 74, 75 Deletion of p66Shc also seems to improve insulin sensitivity in obese diabetic mice on a SV/129 or mixed background, although this effect is controversial. 76 As deletion of p66Shc prevents insulin-resistance, delays aging, and protects from aging-associated diseases, one wonders why p66Shc has been selected and what its physiological role is. Giorgio et al 77 showed that when p66Shc À/À mice were subjected to food competition and exposed to winter temperatures while living in a large outdoor enclosure for a year, they had decreased survival compared with wild-type hybrid C57Bl/6-SV/129 controls. This makes p66Shc a candidate thrifty gene, being evolutionarily selected as advantageous for hunter-gatherer populations, but extremely detrimental when there is constant abundance of food, contributing to the obesity and diabetes epidemics. 78 It has been shown that p66Shc expression is regulated by Sirt1; Zhou and colleagues demonstrated that the repression of p66Shc expression by Sirt1 contributes to the protection of hyperglycemia-induced endothelial dysfunction. 79 Collectively, these studies have identified for the first time an intimate link of these 2 life span-determinant proteins, sirtuin and p66Shc, in the control of vascular homeostasis.
Longevity Genes, Insulin Resistance, and Endothelial Repair
The presence of competent insulin signaling is important not only in the maintenance of endothelial function but also for endothelial regeneration. 80, 81 Repair of a damaged endothelial layer is achieved with the contribution of so-called endothelial progenitor cells (EPCs), 82 which participate in endothelial homeostasis and stimulate the formation of new blood vessels. Shortage of EPCs is considered a mechanism promoting cardiovascular disease development and progression. 83 Despite some uncertainty about their definition, 83, 84 EPCs have been consistently found to be reduced in the peripheral blood of subjects with cardiovascular risk factors, especially in the presence of macroangiopathy. 81, 85, 86 These abnormalities may be implicated in premature aging of the vascular system, which is characterized by a decreased capacity for neovascularization and repair. 87, 88 In this context, insulin resistance exerts additive effects on vascular regenerative capacity. Older humans experience increased bone marrow failure and poorer hematologic tolerance of cytotoxic injury. Indeed, advanced age is a major determinant of bone marrow failure and predicts a poor mobilization response after bone marrow stimulation. 89 G-CSF-induced EPC mobilization is impaired in young and aged diabetic patients compared with controls, resembling an accelerated aging phenotype. 90 A simulation suggests that a small percentage of EPCs homing to the endothelium per year could make a significant contribution to the replicative capacity of the endothelium and the prevention of senescence. 91 Therefore, augmented risk factor-mediated endothelial injury in the absence of sufficient circulating EPCs is expected to enhance the progression of CVD. Several cellular events are associated with premature senescence in progenitor cells. Although there are limited data, Sirt1 appears to play a role in the premature aging of EPCs: mir-34a, which was recently reported to be a tumor suppressor, targets Sirt1. Zhao and colleagues showed that cultured rat EPCs transfected with miR-34a display significant impairment in tube-forming activity, suggesting that miR-34a overexpression decreased EPC angiogenic function; they also revealed that overexpression of miR-34a significantly increased the percentage of SA-b-gal staining, an index of senescence. 42 the relationship between poor metabolic control and EPC number is mediated by Sirt1; they showed that Sirt1 expression is reduced via increased platelet-activating factor receptor activation. Data indicate that p66Shc is also a molecular target to modulate endothelial repair in the setting of metabolic diseases and diabetes. Di Stefano et al 97 found that mouse bone marrow (BM)-derived progenitor cells cultured in high glucose show higher levels of p66Shc gene and protein expression as well as oxidative stress than those exposed to normal glucose levels. Conversely, p66Shc-defective BM cells were not sensitive to high glucose and developed toward the endothelial lineage. The mechanisms were related to preserved eNOS activity, reduced ROS, and accumulated nitrotyrosine. As a functional readout, p66Shc À/À EPCs cultured from SV/129 mouse BM cells showed enhanced angiogenic potency in the Matrigel plug assay in vivo. These data indicate an intimate connection between insulin resistance, longevity genes, and endothelial biology: the network involving sirtuins and p66Shc may include other longevity pathways related to metabolic regulation 98 ( Figure 1 ). It is of utmost importance that the relationship between metabolism and cardiovascular aging involves stem/progenitor cells derived from the bone marrow, which is a reservoir of regenerative cells for several peripheral tissues. 80 
Telomeres, Insulin Resistance, and Progenitor Cells
Telomeres are specific chromatin structures at the ends of eukaryotic chromosomes that prevent the recognition of chromosomal ends as double-stranded DNA breaks, thereby protecting these regions from recombination and degradation. 99 Among proteins associated with telomeric DNA, telomerase and telomeric repeat binding factors 1 and 2 (TRF1, TRF2) regulate telomere length and structure. 100 There is evidence that telomere shortening occurs in human vessels, and this may be related to age-associated vascular changes. 101 Telomere shortening is more prominent in coronary endothelial cells from patients with coronary heart disease compared with cells from healthy subjects. 102, 103 Insulin resistance and diabetes can also affect telomere length, although data in humans are mostly limited to leukocyte telomeres. In the Bogalusa Heart Study, 104 the relative changes in leukocyte telomere length over 10.1 to 12.8 years were correlated with insulin resistance and changes in body mass index. In T2DM patients, the mean monocyte telomere length was significantly lower than in control subjects. 105 In the Framingham Heart Study, leukocyte telomere length from the Offspring cohort was inversely correlated with estimates of insulin sensitivity and indexes of systemic oxidative stress. 106 In the Cardiovascular Health Study, telomere length was inversely related to diabetes, glucose, insulin, diastolic blood pressure, carotid intima-media thickness, and interleukin-6. 107 Telomere dysfunction can induce irreversible cell growth arrest ("cellular senescence"), which is controlled by tumor suppressor proteins such as p53. Minamino and his group 108 showed that p53 expression in adipose tissue is crucially involved in the development of insulin resistance. These observations emphasize possible relationships between telomeres, insulin resistance, and the p53 tumor-suppressor gene in the pathogenesis of cardiovascular disease; indeed, 1 cross-sectional study showed that higher circulating p53 levels are associated with an increase in inflammatory markers, as well as increased carotid intima-media thickness. 109 As p53 is inhibited by Sirt1 and it activates p66Shc, studies are needed to demonstrate the concerted action of these elements on vascular homeostasis (Figure 2 ). Several studies have also found that telomere shortening is a critical determinant of EPC senescence, 110 which can contribute to vascular aging. 111 In healthy men, EPC telomere length was shown to be approximately 20% lower in the older compared with the middle-aged and young men, 112 and leukocyte telomere length is directly associated with circulating EPC levels in young healthy adults. 113 The link between telomere length, EPCs, and senescence is aggravated by the coexistence of risk factor for CVD such as obesity 114 Figure 2 . The molecular interrelationship between the longevity genes Sirt1 and p66Shc in the induction of insulin resistance and endothelial dysfunction. As demonstrated by Zhou et al, 79 Sirt1 represses p66Shc transcription by chromatin remodeling, whereas P53 may be part of this molecular network as a modulator and/or downstream effect. Both reduced Sirt1 and excess p66Shc expression exert negative effects on mature endothelial cells, EPCs, and insulin-responsive cells that regulate metabolism. Along with telomere erosion, these life span-determinant mechanisms induce endothelial dysfunction and insulin resistance, which favor the aging of the cardiovascular system. EPC indicates endothelial progenitor cell. mitochondrial dysfunction, and vascular aging, particularly though induction of progenitor cell senescence.
Therapeutic Implications and Conclusions
Metabolic strategies have been proposed to delay aging, beyond caloric restriction, acting on IIS pathway, sirtuins, mTOR signaling, and AMPK. Certain drugs such metformin, because of their specific mechanism of action, may create a cellular milieu that facilitates longevity. 122 Statins may also exert potential beneficial antiaging activities. Several human progeria syndromes are caused by the accumulation of farnesylated proteins, 123 which are targeted by the pleiotropic effects of statins. 124 Finally, angiotensin II inhibitors may potentially be useful in prolonging life expectancy, as At-II type I receptor (Agtr1a) knockout in mixed C57Bl/6-SV/129 mice increased life span as well as the number of mitochondria, along with upregulation of nicotinamide phosphoribosyltransferase and Sirt3 expression. 125 Insulin resistance disorders are intimately linked to both aging and ED, which is a major driver of CVD. Although CVD remains the major cause of death in Western countries, diabetes and the metabolic syndrome cause a marked shortening of life expectancy. A significant contribution to the accelerated aging process in insulin-resistant individuals is thus attributable to endothelial senescence, dysfunction, and impaired repair. Interestingly, life span-determinant gene products, such as the sirtuins and p66Shc, have metabolic and vascular functions. It can be anticipated that strategies aimed at preserving endothelial health would turn out to be life-span saving, as indirectly suggested by pharmacological intervention studies. Slowing endothelial senescence with a healthy lifestyle, combined with successful control of modifiable risk factors, may thus circumvent the ineluctable power of the genetic background. Targeted intervention on endothelial aging pathways is the next challenge.
Pending Issues
A direct role of altered expression of longevity-related genes in predicting the development or progression of metabolic disorders is still lacking. Furthermore, it is unknown whether therapies acting on longevity-associated pathways modify the clinical course of diabetic patients. A prolongevity (benevolent) condition of insulin resistance may be considered an evolutionarily conserved attempt to protect insulin-dependent tissues from excess intracellular glucose. 126 It is unclear whether ED has a role in mediating the protective effect of benevolent insulin resistance on longevity.
The effect of the control of metabolic diseases such as diabetes on aging-associated genes is unknown, as are the effects of lifestyle interventions that improve endothelial function. 
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